A thread through the archive
Essays tagged “healthcare regulation”. Follow an idea across the archive.
Scott Alexander corrects and expands on the story of Omegaven, a life-saving infant nutritional fluid, using it to illustrate systemic issues with medical regulation and drug approval.
Scott Alexander argues that the FDA is too strict, not too lax, and proposes unbundling FDA approval to allow for more nuanced drug regulation.
Scott Alexander argues that the 33% rate of post-marketing safety events for FDA-approved drugs is not necessarily concerning and explains why post-marketing surveillance is a normal part of drug safety monitoring.
Scott Alexander drafts a letter to the FDA arguing against their decision to halt 23andMe's genetic testing services, highlighting the benefits and addressing the FDA's concerns.